Last updated: February 28, 2026
What is Ustekinumab?
Ustekinumab is a monoclonal antibody targeting interleukin-12 and interleukin-23. It is used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. The drug is marketed under the brand name Stelara by Janssen, with approval granted in multiple regions including the US, EU, and Japan. Its patent protection expires in most markets by 2030, creating opportunities for biosimilars.
What Are the Primary Excipient Uses in Ustekinumab Formulations?
Ustekinumab formulations utilize specific excipients to maintain stability, enhance solubility, and ensure proper delivery. The key excipients include:
- Polysorbate 80: Stabilizes protein aggregation, reduces surface adsorption.
- Sugars (sucrose, trehalose): Protects against denaturation during freeze-thaw cycles.
- Histidine buffers: Maintains pH stability.
- Polysorbate 20: Alternative surfactant to reduce aggregation.
- Water for injection: Solvent base.
The current formulations typically contain these excipients in concentrations tailored to injectable prefilled syringes (0.5 mL or 1 mL). Exact excipient levels are proprietary but are designed to optimize stability over a shelf life of up to 24 months at refrigerated temperatures (2°C to 8°C).
What Are the Challenges & Opportunities in Excipient Selection for Biosimilar Development?
Challenges:
- Regulatory approval requires demonstration of equivalency in excipient effects on stability and immunogenicity.
- Excipients like polysorbates can undergo degradation, leading to variability.
- Ensuring compatibility with existing formulations without compromising efficacy.
Opportunities:
- Substituting excipients with less immunogenic or more stable alternatives (e.g., using polysorbate 20 over polysorbate 80).
- Incorporating advanced excipients that improve stability at room temperature, extending shelf life.
- Developing formulations that enable easier administration, such as long-acting depots.
How Do Excipient Strategies Impact Commercial Opportunities?
Choosing optimal excipients influences manufacturing costs, storage, distribution, and patient compliance. Key considerations:
- Cost reduction: Using more stable or less expensive excipients can lower production costs.
- Shelf stability: Longer shelf life reduces waste and adds appeal in regions with limited cold chain logistics.
- Enhanced bioavailability: Formulations improving solubility or reducing aggregation can broaden patient acceptance.
- Regulatory approval: Compatibility with biosimilar approval pathways depends on rigorous demonstration of excipient equivalence.
A strategic excipient selection can position biosimilar manufacturers competitively by offering reliable, cost-effective, and patient-friendly products.
What Are the Patent and Market Dynamics Surrounding Excipient Use?
Patent landscapes focus mainly on the molecular patent of ustekinumab itself. Excipients are generally considered non-patented unless linked to novel formulations. Biosimilar entrants rely on excipient parity; any change requires regulatory approval.
Market opportunities arise by:
- Developing formulations with improved excipients that extend shelf life and reduce costs.
- Creating easier-to-administer formats such as prefilled syringes with compatible excipients.
- Offering products with comparable or improved stability profiles for emerging markets.
What Future Trends Are Likely in Excipient Use for Ustekinumab?
Emerging trends include:
- Use of cell culture media residuals as excipients to reduce immunogenic risk.
- Incorporation of stabilizers tailored for self-administration.
- Development of lyophilized formulations with excipients that enhance stability during transportation.
- Adoption of biodegradable or plant-based excipients to meet sustainability goals.
Key Takeaways
- Ustekinumab formulations rely on excipients like polysorbates, sugars, and buffers for stability.
- Biosimilar development requires excipient equivalence, with regulatory compliance critical.
- Excipient innovation can reduce costs, extend shelf life, and improve patient adherence.
- Market opportunities exist through formulation improvements, especially in emerging markets.
- Future advances will focus on stability, sustainability, and ease of administration.
FAQs
1. How do excipients influence the immunogenicity of ustekinumab?
Excipients like polysorbates can provoke immune responses if degraded or contaminated. Selecting stable, low immunogenic excipients minimizes this risk.
2. Are there regulatory restrictions on excipients in biosimilar formulations?
Yes. Biosimilar approval requires demonstrating that excipient changes do not alter safety, efficacy, or immunogenicity profiles compared to the reference product.
3. Can substituting excipients open opportunities for biosimilar differentiation?
Yes. Using more stable or patient-friendly excipients can improve product stability, reduce costs, and enhance patient compliance.
4. What role does shelf life extension play in market expansion?
Longer shelf life reduces cold chain dependency, lowers waste, and improves access in regions with limited distribution infrastructure.
5. Will patient preferences influence excipient selection in future formulations?
Yes. Formulations that enable prefilled, premeasured, or easier-to-inject products tend to improve adherence, influencing excipient choices.
References
[1] European Medicines Agency. (2019). Stelara (ustekinumab) summary of product characteristics.
[2] U.S. Food and Drug Administration. (2016). Stelara (ustekinumab) prescribing information.
[3] Jain, T., et al. (2020). Advances in pharmaceutical excipient technology: a review. Journal of Pharmaceutical Sciences, 109(3), 617-629.
